A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants

NCT02478333 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG: ALS-008176 (250 mg)
DRUG: ALS-008176 (500 mg)
DRUG: ALS-008176 (750 mg)
OTHER: Placebo

Sponsor

Janssen Pharmaceutical K.K.